Jianjun Li

Jianjun Li

Auto-generated profile, based on publicly available information

Jianjun Li

Department of Spine surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MXMaolin Xiao
Maolin Xiao
JLJianjun Li
Jianjun Li
QLQingyuan Liu
Qingyuan Liu
XHXiangbiao He
Xiangbiao He
ZYZongke Yang
Zongke Yang
DWDelin Wang
Delin Wang
Tripartite motif (TRIM) protein family proteins contain more than 80 members in humans, and most of these proteins exhibit E3 ubiquitin ligase activity mediated through a RING finger domain. Their biological functions are very complex, and they perform diverse functions in cell evolution processes, such as intracellular signaling, development, apoptosis, protein quality control, innate immunity, autophagy, and carcinogenesis. Tripartite motif‐containing protein 2 (TRIM2), a member of the TRIM superfamily, is an 81 kDa multidomain protein, also known as CMT2R or RNF86, located at 4q31.3. TRIM2 functions as an E3 ubiquitin ligase. Current studies have shown that TRIM2 can play roles in neuroprotection, neuronal rapid ischemic tolerance, antiviral responses, neurological diseases, etc. Moreover, based on some studies in tumors, TRIM2 regulates tumor proliferation, migration, invasion, apoptosis, and drug resistance through different mechanisms and plays a critical role in tumor occurrence and development. This review is aimed at providing a systematic and comprehensive summary of research on TRIM2 and at exploring the potential role of TRIM2 as a biomarker and therapeutic target in many kinds of human diseases.

8 May 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
JLJianjun Li
Jianjun Li
CYCheng Yu
Cheng Yu
JCJunjie Cheng
Junjie Cheng
YCYanlin Cao
Yanlin Cao
TLTao Lin
Tao Lin
YDYang Duan
Yang Duan
Lumbar spinal stenosis (LSS) caused by hypertrophy of the ligamentum flavum (HLF) is a major cause of lower limb dysfunction; however, its underlying pathogenesis remains unclear. Here we show that metabolic reprogramming and epigenetic modifications synergistically drive HLF progression through a glycolysis-lactylation-fibrosis axis. We demonstrate that HLF tissues exhibit enhanced glycolysis, characterized by elevated extracellular acidification rate, increased ATP production, and upregulated glycolytic enzymes, along with lactate accumulation that positively correlates with tissue thickness. Mass spectrometry identifies CRYAB lysine 92 lactylation (CRYAB_K92la) as a significantly upregulated modification in HLF. Lactylation at CRYAB_K92 promotes fibrosis in human ligamentum flavum cells, whereas the lactylation-blocking mutation CRYAB_K92R attenuates lactate-induced fibrosis and proliferation. Mechanistically, CRYAB_K92 enhances S100A16 transcription, stabilizes S100A16 protein by inhibiting its degradation, and strengthens CRYAB-S100A16 binding, collectively upregulating S100A16 expression. Upregulated S100A16 activates the RAGE signaling pathway, further promoting lactate release and ATP production, thereby forming a positive feedback loop that perpetuates glycolysis, lactate generation, and fibrosis. These findings reveal a novel regulatory axis in HLF pathogenesis and identify CRYAB lactylation, S100A16, and the RAGE pathway as potential therapeutic targets for LSS.

21 August 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
LZLuqi Zhu
Luqi Zhu
YHYunTeng Hu
YunTeng Hu
SKShuxian Kuang
Shuxian Kuang
KZKexuan Zhang
Kexuan Zhang
HLHuanbin Lin
Huanbin Lin
JLJianjun Li
Jianjun Li